rdus-20210630
0001428522FALSE--12-312021Q2http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member0.020489100014285222021-01-012021-06-30xbrli:shares00014285222021-07-30iso4217:USD00014285222021-06-3000014285222020-12-31iso4217:USDxbrli:shares0001428522us-gaap:ProductMember2021-04-012021-06-300001428522us-gaap:ProductMember2020-04-012020-06-300001428522us-gaap:ProductMember2021-01-012021-06-300001428522us-gaap:ProductMember2020-01-012020-06-300001428522us-gaap:LicenseMember2021-04-012021-06-300001428522us-gaap:LicenseMember2020-04-012020-06-300001428522us-gaap:LicenseMember2021-01-012021-06-300001428522us-gaap:LicenseMember2020-01-012020-06-3000014285222021-04-012021-06-3000014285222020-04-012020-06-3000014285222020-01-012020-06-300001428522us-gaap:RetainedEarningsMember2020-01-012020-06-300001428522us-gaap:CommonStockMember2020-03-310001428522us-gaap:AdditionalPaidInCapitalMember2020-03-310001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001428522us-gaap:RetainedEarningsMember2020-03-3100014285222020-03-310001428522us-gaap:RetainedEarningsMember2020-04-012020-06-300001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001428522us-gaap:CommonStockMember2020-04-012020-06-300001428522us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001428522us-gaap:CommonStockMember2020-06-300001428522us-gaap:AdditionalPaidInCapitalMember2020-06-300001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001428522us-gaap:RetainedEarningsMember2020-06-3000014285222020-06-300001428522us-gaap:CommonStockMember2021-03-310001428522us-gaap:AdditionalPaidInCapitalMember2021-03-310001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001428522us-gaap:RetainedEarningsMember2021-03-3100014285222021-03-310001428522us-gaap:RetainedEarningsMember2021-04-012021-06-300001428522us-gaap:CommonStockMember2021-04-012021-06-300001428522us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001428522us-gaap:CommonStockMember2021-06-300001428522us-gaap:AdditionalPaidInCapitalMember2021-06-300001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001428522us-gaap:RetainedEarningsMember2021-06-300001428522us-gaap:CommonStockMember2019-12-310001428522us-gaap:AdditionalPaidInCapitalMember2019-12-310001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001428522us-gaap:RetainedEarningsMember2019-12-3100014285222019-12-310001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001428522us-gaap:CommonStockMember2020-01-012020-06-300001428522us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001428522us-gaap:CommonStockMember2020-12-310001428522us-gaap:AdditionalPaidInCapitalMember2020-12-310001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001428522us-gaap:RetainedEarningsMember2020-12-3100014285222020-01-012020-12-310001428522us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001428522us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001428522srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001428522us-gaap:RetainedEarningsMember2021-01-012021-06-300001428522us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001428522us-gaap:CommonStockMember2021-01-012021-06-300001428522us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001428522us-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-01-010001428522srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-01-0100014285222021-01-010001428522us-gaap:CashMember2021-06-300001428522us-gaap:MoneyMarketFundsMember2021-06-300001428522us-gaap:CashMember2020-12-310001428522us-gaap:MoneyMarketFundsMember2020-12-310001428522us-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310001428522rdus:DomesticCorporateCommercialPaperMember2020-12-31rdus:security0001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashMember2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMemberus-gaap:FairValueInputsLevel3Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMember2021-06-300001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMemberus-gaap:FairValueInputsLevel3Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberrdus:DomesticCorporateCommercialPaperMemberus-gaap:FairValueInputsLevel1Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberrdus:DomesticCorporateCommercialPaperMemberus-gaap:FairValueInputsLevel2Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberrdus:DomesticCorporateCommercialPaperMemberus-gaap:FairValueInputsLevel3Member2020-12-310001428522us-gaap:FairValueMeasurementsRecurringMemberrdus:DomesticCorporateCommercialPaperMember2020-12-310001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2017-08-14xbrli:pure0001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2017-09-120001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMemberus-gaap:AdditionalPaidInCapitalMember2017-09-120001428522us-gaap:LongTermDebtMemberus-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2017-09-120001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2017-08-142017-09-120001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-01-010001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2017-08-142017-09-12rdus:dayrdus:business_day0001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2017-08-142017-09-120001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2017-08-142017-09-120001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2021-03-310001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2021-03-012021-03-310001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2021-01-012021-06-300001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2021-06-300001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2021-04-012021-06-300001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2020-04-012020-06-300001428522us-gaap:ConvertibleDebtMemberrdus:ThreePointZeroPercentConvertibleNotesMember2020-01-012020-06-300001428522rdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-03-030001428522rdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-01-012021-01-310001428522us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-03-030001428522us-gaap:LondonInterbankOfferedRateLIBORMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-03-032021-03-030001428522rdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-03-032021-03-030001428522us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-03-032021-03-030001428522us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-03-032021-03-030001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-03-112021-03-110001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-03-110001428522rdus:TermFacilityMemberus-gaap:MediumTermNotesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-06-300001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-04-012021-06-300001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2020-04-012020-06-300001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2021-01-012021-06-300001428522rdus:DebtInstrumentTrancheOneMemberrdus:TermFacilityMemberus-gaap:MediumTermNotesMember2020-01-012020-06-300001428522us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001428522us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001428522us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001428522us-gaap:EmployeeStockOptionMember2020-04-012020-06-300001428522us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001428522us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001428522us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001428522us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-06-300001428522us-gaap:PerformanceSharesMember2021-01-012021-06-300001428522us-gaap:PerformanceSharesMember2021-04-012021-06-300001428522us-gaap:PerformanceSharesMember2020-01-012020-06-300001428522us-gaap:PerformanceSharesMember2020-04-012020-06-300001428522rdus:PerformanceStockOptionMember2021-01-012021-06-300001428522rdus:PerformanceStockOptionMember2021-04-012021-06-300001428522rdus:PerformanceStockOptionMember2020-01-012020-06-300001428522rdus:PerformanceStockOptionMember2020-04-012020-06-300001428522rdus:AllowanceforChargebacksDiscountsandFeesMember2019-12-310001428522rdus:AllowanceforGovernmentandOtherRebatesMember2019-12-310001428522us-gaap:SalesReturnsAndAllowancesMember2019-12-310001428522rdus:ProductRevenueAllowanceandReservesMember2019-12-310001428522rdus:AllowanceforChargebacksDiscountsandFeesMember2020-01-012020-06-300001428522rdus:AllowanceforGovernmentandOtherRebatesMember2020-01-012020-06-300001428522us-gaap:SalesReturnsAndAllowancesMember2020-01-012020-06-300001428522rdus:ProductRevenueAllowanceandReservesMember2020-01-012020-06-300001428522rdus:AllowanceforChargebacksDiscountsandFeesMember2020-06-300001428522rdus:AllowanceforGovernmentandOtherRebatesMember2020-06-300001428522us-gaap:SalesReturnsAndAllowancesMember2020-06-300001428522rdus:ProductRevenueAllowanceandReservesMember2020-06-300001428522rdus:AllowanceforChargebacksDiscountsandFeesMember2020-12-310001428522rdus:AllowanceforGovernmentandOtherRebatesMember2020-12-310001428522us-gaap:SalesReturnsAndAllowancesMember2020-12-310001428522rdus:ProductRevenueAllowanceandReservesMember2020-12-310001428522rdus:AllowanceforChargebacksDiscountsandFeesMember2021-01-012021-06-300001428522rdus:AllowanceforGovernmentandOtherRebatesMember2021-01-012021-06-300001428522us-gaap:SalesReturnsAndAllowancesMember2021-01-012021-06-300001428522rdus:ProductRevenueAllowanceandReservesMember2021-01-012021-06-300001428522rdus:AllowanceforChargebacksDiscountsandFeesMember2021-06-300001428522rdus:AllowanceforGovernmentandOtherRebatesMember2021-06-300001428522us-gaap:SalesReturnsAndAllowancesMember2021-06-300001428522rdus:ProductRevenueAllowanceandReservesMember2021-06-300001428522rdus:TeijinAgreementMemberus-gaap:CollaborativeArrangementMember2017-07-012017-07-3100014285222017-07-012017-07-310001428522rdus:TeijinAgreementMemberus-gaap:CollaborativeArrangementMember2021-03-012021-03-310001428522rdus:TeijinAgreementMemberus-gaap:CollaborativeArrangementMemberus-gaap:LicenseMember2021-01-012021-06-300001428522rdus:MenariniGroupMember2021-01-012021-06-300001428522rdus:MenariniGroupMembersrt:MaximumMember2021-01-012021-06-300001428522rdus:A3MCompanyand3MInnovativePropertiesCompanyMemberus-gaap:CollaborativeArrangementMember2018-02-272018-02-270001428522rdus:A3MAndKindevaMemberus-gaap:CollaborativeArrangementMemberrdus:A3MCompanyand3MInnovativePropertiesCompanyMember2018-02-272021-06-300001428522rdus:A3MCompanyand3MInnovativePropertiesCompanyMemberus-gaap:CollaborativeArrangementMember2018-02-012018-02-280001428522rdus:A3MCompanyand3MInnovativePropertiesCompanyMemberus-gaap:CollaborativeArrangementMember2018-02-272021-06-300001428522rdus:YpsomedMember2017-06-012017-06-30iso4217:CHF0001428522rdus:YpsomedMember2020-05-012020-05-310001428522rdus:VetterMember2017-06-012017-06-300001428522rdus:LonzaMember2016-06-012016-06-30iso4217:EUR0001428522rdus:FreshCutDevelopmentLLCMember2020-01-012020-12-310001428522rdus:A3MCompanyand3MInnovativePropertiesCompanyMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310001428522rdus:FreshCutDevelopmentLLCMember2021-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2021
Or
         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from              to             .
 
Commission File Number 001-35726
 
Radius Health, Inc.
(Exact name of registrant as specified in its charter)
Delaware 80-0145732
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
 
22 Boston Wharf Road, 7th Floor
Boston, Massachusetts 02210
(Address of Principal Executive Offices and Zip Code)
 
(617) 551-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareRDUSThe Nasdaq Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes   No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes   No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer 
  
Non-accelerated filer Smaller reporting company 
Emerging growth company 


Table of Contents
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No

Number of shares of the registrant’s Common Stock, $0.0001 par value per share, outstanding as of July 30, 2021: 47,266,146 shares


Table of Contents
RADIUS HEALTH, INC.
FORM 10-Q
FOR THE QUARTER ENDED JUNE 30, 2021
TABLE OF CONTENTS
 
   
 
 
 6
 
   
   
   


Table of Contents
PART I— FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Radius Health, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share amounts)
June 30,
2021
December 31,
2020
 (unaudited) 
ASSETS  
Current assets:  
Cash and cash equivalents$99,173 $91,436 
Restricted cash567 567 
Marketable securities 23,280 
Accounts receivable, net23,638 20,310 
Inventory11,310 9,174 
Prepaid expenses11,402 13,279 
Other current assets38,461 22,502 
Total current assets184,551 180,548 
Property and equipment, net702 796 
Intangible assets5,385 5,785 
Right of use assets - operating leases740 3,933 
Other assets1,487 520 
Total assets$192,865 $191,582 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)  
Current liabilities:  
Accounts payable$14,562 $9,925 
Accrued expenses and other current liabilities66,085 59,758 
Deferred revenue 1,000 
Operating lease liability, current1,121 2,490 
Total current liabilities81,768 73,173 
Convertible notes payable190,065 213,645 
Term loan147,848 24,905 
Operating lease liability, long term261 3,518 
Total liabilities419,942 315,241 
Stockholders’ equity (deficit):  
Common stock, 0.0001 par value; 200,000,000 shares authorized, 47,255,094 shares and 46,779,479 shares issued and outstanding at June 30, 2021 and December 31, 2020
5 5 
Additional paid-in-capital1,103,282 1,222,137 
Accumulated other comprehensive income 21 
Accumulated deficit(1,330,364)(1,345,822)
Total stockholders’ equity (deficit)(227,077)(123,659)
Total liabilities and stockholders’ equity (deficit)$192,865 $191,582 
See accompanying notes to unaudited condensed consolidated financial statements.


Table of Contents
Radius Health, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited, in thousands, except share and per share amounts)
Three Months Ended
June 30,
Six Months Ended
June 30,
 2021202020212020
REVENUES:
Product revenue, net$51,797 $50,113 $97,057 $98,037 
License revenue  11,000  
Total revenue$51,797 $50,113 $108,057 $98,037 
OPERATING EXPENSES:  
Cost of sales - product4,394 4,070 8,319 7,931 
Cost of sales - intangible amortization200 200 399 399 
Research and development, net of amounts reimbursable (a)26,950 44,881 58,391 83,890 
Selling, general and administrative32,143 38,231 66,240 74,664 
Income (Loss) from operations(11,890)(37,269)(25,292)(68,847)
OTHER INCOME (EXPENSE):    
Other (expense) income(79)(68)(80)(59)
Interest expense(4,847)(6,922)(9,211)(13,678)
Interest income6 379 64 1,050 
Gain on extinguishment of debt  1,960  
NET LOSS$(16,810)$(43,880)$(32,559)$(81,534)
OTHER COMPREHENSIVE LOSS:    
Unrealized loss from available-for-sale debt securities 774 (21)105 
COMPREHENSIVE LOSS$(16,810)$(43,106)$(32,580)$(81,429)
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 8)$(16,810)$(43,880)$(32,559)$(81,534)
LOSS PER SHARE:    
Basic and diluted$(0.35)$(0.95)$(0.69)$(1.76)
WEIGHTED AVERAGE SHARES:    
Basic and diluted47,391,530 46,420,046 47,114,947 46,345,585 
(a) Amounts reimbursable for the three and six months ended June 30, 2021 were $18.5 million and $32.8 million, respectively, and $0 for the three and six months ended June 30, 2020.

See accompanying notes to unaudited condensed consolidated financial statements.


5

Table of Contents
Radius Health, Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(Unaudited, in thousands, except share and per share amounts)
 Stockholders’ Equity (Deficit)
 Common StockAdditional Paid-In Capital 
Accumulated Other
Comprehensive Income
(Loss)
 Accumulated
Deficit
Total Stockholders’ Equity (Deficit)
 SharesAmountAmount Amount AmountAmount
Balance at March 31, 202046,387,437 $5 $1,200,776 $(666)$(1,274,268)$(74,153)
Net loss(43,880)(43,880)
Unrealized gain from available-for-sale securities774 774 
Vesting of restricted shares61,054  
Share-based compensation expense7,840 7,840 
Balance at June 30, 202046,448,491 $5 $1,208,616 $108 $(1,318,148)$(109,419)
Balance at March 31, 202147,241,098 $5 $1,097,539 $ $(1,313,554)$(216,010)
Net loss(16,810)(16,810)
Vesting of restricted shares11,621  
Exercise of options2,375 40 40 
Share-based compensation expense5,703 5,703 
Balance at June 30, 202147,255,094 $5 $1,103,282 $ $(1,330,364)$(227,077)
See accompanying notes to unaudited condensed consolidated financial statements.



















6

Table of Contents
Radius Health Inc.
Condensed Consolidated Statement of Shareholders’ Equity (Deficit)
(Unaudited, in thousands, except share and per share amounts)

Shareholders’ Equity (Deficit)
Common StockAdditional Paid in CapitalAccumulated Other Comprehensive IncomeAccumulated DeficitTotal Stockholders’ Equity (Deficit)
SharesAmountAmountAmountAmountAmount
Balance at December 31, 201946,189,870 5 1,194,327 3 (1,236,614)(42,279)
Net loss(81,534)(81,534)
Unrealized gain from available-for-sale securities105 105 
Vesting of restricted shares203,324  
Issuance of common stock upon purchase by employee stock purchase plan55,297 990 990 
Share-based compensation expense13,299 13,299 
Balance at June 30, 202046,448,491 $5 $1,208,616 $108 $(1,318,148)$(109,419)
Balance at December 31, 202046,779,479 5 1,222,137 21 (1,345,822)(123,659)
Adjustment due to adoption of ASU 2020-06(134,450)48,017 (86,433)
Net loss(32,559)(32,559)
Unrealized loss from available-for-sale securities(21)(21)
Vesting of restricted shares213,639  
Exercise of options195,675 3,804 3,804 
Issuance of common stock upon purchase by employee stock purchase plan66,301 678 678 
Share-based compensation expense11,113 11,113 
Balance at June 30, 202147,255,094 $5 $1,103,282 $ $(1,330,364)$(227,077)
See accompanying notes to unaudited condensed consolidated financial statements.
7

Table of Contents
Radius Health, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
Six Months Ended
June 30,
 20212020
CASH FLOWS USED IN OPERATING ACTIVITIES:  
Net loss$(32,559)$(81,534)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation and amortization494 945 
Amortization of premium/discount on marketable securities, net19 132 
Amortization of debt discount and debt issuance costs771 8,725 
Stock-based compensation11,113 13,299 
Gain on extinguishment of debt(1,960) 
Gain on the lease termination(901) 
Changes in operating assets and liabilities:  
Inventory(2,136)(583)
Accounts receivable, net(3,328)5,390 
Prepaid expenses1,877 4,210 
Other current assets(15,959)(992)
Operating lease right of use assets667 1,027 
Other long-term assets(967) 
Accounts payable4,637 5,688 
Deferred revenue(1,000) 
Accrued expenses and other current liabilities6,327 (1,274)
Lease liability, operating leases(1,199)(1,102)
Net cash used in operating activities(34,104)(46,069)
CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:  
Purchases of marketable securities (39,907)
Sales and maturities of marketable securities23,240 61,400 
Net cash provided by investing activities23,240 21,493 
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:  
Proceeds from exercise of stock options3,804  
Proceeds from issuance of term loan, net of issuance costs122,687 9,939 
Repurchase of convertible notes(108,568) 
Proceeds from issuance of shares under employee stock purchase plan678 990 
Net cash provided by financing activities18,601 10,929 
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH7,737 (13,647)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF PERIOD92,003 70,453 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD$99,740 $56,806 
SUPPLEMENTAL DISCLOSURES:  
Cash paid for interest$7,622 $4,818 
Cash paid for amounts included in the measurement of operating lease liabilities$1,340 $1,175 
Right of use assets obtained in exchange for operating lease liability$332 $1,110 
See accompanying notes to unaudited condensed consolidated financial statements.

8

Table of Contents
Radius Health, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Organization
Radius Health, Inc. (“Radius,” the “Company,” “us,” “our” or “we”) is a commercial biopharmaceutical company committed to serving patients with unmet medical needs in endocrinology and other therapeutic areas. In April 2017, the Company’s first commercial product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. We are a party to a license and development agreement with Teijin Limited (“Teijin”) for abaloparatide for subcutaneous injection (“abaloparatide-SC”) in Japan. In March 2021, Teijin received approval in Japan for Ostabaro® abaloparatide acetate for the treatment of osteoporosis and for promotion of bone formation in both female and male patients with high risk of fracture. The Company is developing an abaloparatide transdermal system, or abaloparatide-TD, for potential use in the treatment of postmenopausal women with osteoporosis. We are also developing RAD011, a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes. We are initiating plans to move forward with a pivotal Phase 2/3 study of RAD011 for treatment of hyperphagia-related behavior in patients with Prader-Willi Syndrome.
The Company is subject to risks common to companies in its industry including, but not limited to, the dependence on revenues from a single commercialized product, competition, uncertainty about clinical trial outcomes and regulatory approvals, uncertainties relating to pharmaceutical pricing reimbursement, uncertain protection of proprietary technology and potential product liability. As of June 30, 2021, the Company had an accumulated deficit of $1,330.4 million, and total cash and cash equivalents of $99.2 million.
Based upon its cash and cash equivalents balance as of June 30, 2021, the Company believes that it has sufficient capital as well as access to other capital discussed in Note 7, “Term Loan and Credit Facility”, to fund its commercial operations, development plans, and other operational activities for at least one year from the date of this filing. The Company expects to finance the future development costs of its clinical product portfolio with its product revenue, existing cash and cash equivalents, or through strategic financing opportunities that could include, but are not limited to collaboration agreements, cash provided by operations or the incurrence of debt. However, there is no guarantee that any strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders.
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation—The accompanying unaudited condensed consolidated financial statements and the related disclosures of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included.
When preparing financial statements in conformity with U.S. GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2021. Subsequent events have been evaluated up to the date of issuance of these financial statements. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 25, 2021.
Significant Accounting Policies—The significant accounting policies identified in the Company’s 2020 Form 10-K that require the Company to make estimates and assumptions include: revenue recognition, inventory obsolescence, long-lived assets and intangible assets, accounting for stock-based compensation, contingencies, tax valuation reserves, fair value measures, and accrued expenses. There were no changes to significant accounting policies during the six months ended June 30, 2021, except for the adoption of the Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”) detailed below.
Accounting Standards Updates, Recently Adopted— In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The guidance
9

Table of Contents
simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity. Consequently, a convertible debt instrument, such as the Company’s convertible notes, will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments and requires additional disclosures. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.
The Company elected to early adopt this guidance effective January 1, 2021 under the modified retrospective adoption approach and the comparative information has not been restated and continues to be presented according to accounting standards in effect for those periods. The cumulative effect of the change was recognized as an adjustment to the opening balance of accumulated deficit at the date of adoption and our convertible notes due September 1, 2024 are no longer bifurcated into separate liability and equity components. The principal amount of our convertible notes due September 2024 is classified as a liability only in the condensed consolidated balance sheet for the period ended June 30, 2021. Upon adoption of ASU 2020-06, we recorded an adjustment to the convertible notes liability component, equity component (additional paid-in-capital) and accumulated deficit. This adjustment was calculated based on the carrying amount of the convertible notes as if it had always been treated as a liability only. Furthermore, we recorded an adjustment to the debt issuance costs contra liability and equity (additional paid-in-capital) components under the same premise, as if debt issuance costs had always been treated as a contra liability only. In addition, we derecognized deferred income tax liabilities associated with the equity component of the convertible notes, which the impact is fully offset by the change in valuation allowance. Lastly, interest expense related to the accretion of our convertible notes due September 1, 2024 is no longer recognized.
The following table summarizes the cumulative effect of the changes to our condensed consolidated balance sheet as of January 1, 2021 as compared to December 31, 2020 from the adoption of ASU 2020-06:
Consolidated Balance sheet Data (in thousands)Balance at
December 31, 2020
Adjustment due to ASU 2020-06 adoptionBalance at
January 1, 2021
Liabilities
Convertible notes payable (1)$213,645 $86,433 $300,078 
Equity
Additional paid-in-capital $1,222,137 $(134,450)$1,087,687 
Accumulated deficit$(1,345,822)$48,017 $(1,297,805)
                                                                                                                                                                                             
(1)                           Convertible notes payable is presented net of unamortized discount and debt issuance costs of $88.1 million and $3.2 million, respectively at December 31, 2020. Convertible notes payable is presented net of unamortized discount and debt issuance costs of $4.7 million and $0.3 million at January 1, 2021.
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interest period and the recognition of deferred tax liabilities for outside basis differences, and also clarifies and simplifies other aspects of the accounting for income taxes. The amendments under ASU 2010-12 are effective for interim and annual fiscal periods beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance on January 1, 2021 and it did not have a material impact on its financial statements.
3. Marketable Securities
Available-for-sale marketable securities and cash and cash equivalents as of June 30, 2021 and December 31, 2020 consisted of the following (in thousands):
10

Table of Contents
 June 30, 2021
 Amortized Cost ValueGross 
Unrealized 
Gains
Gross 
Unrealized 
Losses
Fair Value
Cash and cash equivalents:    
Cash$28,924 $— $— $28,924 
Money market funds70,249 — — 70,249 
Total$99,173 $— $— $99,173 
 
 December 31, 2020
 Amortized Cost ValueGross 
Unrealized 
Gains
Gross 
Unrealized 
Losses
Fair Value
Cash and cash equivalents:    
Cash$44,616 $— $— $44,616 
Money market funds46,820 — — 46,820 
Total$91,436 $— $— $91,436 
Marketable securities:    
Domestic corporate debt securities$18,266 $21 $(2)$18,285 
Domestic corporate commercial paper4,993 2  4,995 
Total$23,259 $23 $(2)$23,280 
The Company reviews marketable securities whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. We evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive income.
Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense on the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale debt security is confirmed or when either of the criteria regarding intent or requirement to sell is met. There was one available-for-sale debt security in an unrealized loss position at December 31, 2020 for which an allowance for credit losses was not recorded as it was attributable to changes in interest rates and the Company did not believe any unrealized losses represented credit losses. There were no available-for-sale debt securities or unrealized losses at June 30, 2021.
4. Fair Value Measurements
The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Below are the three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
11

Table of Contents
Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no material transfers between any levels during the six months ended June 30, 2021. There were no material transfers between any levels during 2020.
The following table summarizes the financial instruments measured at fair value on a recurring basis in the Company’s accompanying condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020 (in thousands):
 As of June 30, 2021
 Level 1Level 2Level 3Total
Assets    
Cash and cash equivalents:    
Cash$28,924 $ $ $28,924 
Money market funds (1)70,249   70,249 
Total$99,173 $ $ $99,173 
 
 As of December 31, 2020
 Level 1Level 2Level 3Total
Assets    
Cash and cash equivalents:    
Cash$44,616 $ $ $44,616 
Money market funds (1)46,820   46,820 
Total$91,436 $ $ $91,436 
Marketable Securities    
Domestic corporate debt securities (2)$ $18,285 $ $18,285 
Domestic corporate commercial paper (2) 4,995  4,995 
Total$ $23,280 $ $23,280 
(1)                           Fair value is based upon quoted market prices.
(2)                           Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources, including market participants, dealers and brokers.
As of June 30, 2021, the carrying amounts of the cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses, long-term debt and operating lease liabilities approximated their estimated fair values.
5. Inventory
Inventory consisted of the following as of June 30, 2021 and December 31, 2020 (in thousands):
June 30,
2021
December 31,
2020
Raw materials$7,466 $5,228 
Work in process 667 
Finished goods3,844 3,279 
Total inventories$11,310 $9,174 
Finished goods manufactured by the Company have a 36-month shelf life from date of manufacture.
6. Convertible Notes Payable
On August 14, 2017, in a registered underwritten public offering, the Company issued $300.0 million aggregate principal amount of 3% Convertible Senior Notes due September 1, 2024 (the “Convertible Notes”). In addition, on September 12, 2017, the Company issued an additional $5.0 million principal amount of Convertible Notes pursuant to the exercise of an over-allotment option granted to the underwriters in the offering. In accordance with accounting guidance for debt with conversion and other options, and prior to the adoption of ASU 2020-05 on January 1, 2021, the Company separately accounted for the
12

Table of Contents
liability component (the “Liability Component”) and embedded conversion option (the “Equity Component”) of the Convertible Notes by allocating the proceeds between the Liability Component and the Equity Component, due to the Company’s ability to settle the Convertible Notes in cash, common stock or a combination of cash and common stock, at its option. In connection with the issuance of the Convertible Notes, the Company incurred approximately $9.4 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the Liability and Equity Components based on the allocation of the proceeds. Of the total $9.4 million of debt issuance costs, $4.3 million was allocated to the Equity Component and recorded as a reduction to additional paid-in capital and $5.1 million was allocated to the Liability Component and is now recorded as a reduction of the Convertible Notes in the Company’s condensed consolidated balance sheet.
Prior to the adoption of ASU 2020-06 on January 1, 2021, the initial carrying amount of the Liability Component of $166.3 million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected the Company’s non-convertible debt borrowing rate for similar debt. The Equity Component of the Convertible Notes of $138.7 million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Convertible Notes of $305.0 million and the fair value of the Liability of the Convertible Notes of approximately $305.0 million on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount (the “Debt Discount”) is amortized to interest expense using the effective interest method over seven years. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification. In connection with issuance of the Convertible Notes, the Company also incurred certain offering costs directly attributable to the offering. Such costs are deferred and amortized over the term of the debt to interest expense using the effective interest method.
Subsequent to the adoption of ASU 2020-06 on January 1, 2021, which the Company elected to adopt using the modified retrospective method, the Company removed the impact of recognizing the Equity Component of the Convertible Notes (at issuance and the subsequent accounting impact of additional interest expense from debt discount amortization). The cumulative effective of the accounting change as of January 1, 2021 was an increase to the carrying amount of the convertible notes of $86.4 million, a reduction to accumulated deficit of $48.0 million, and a reduction to additional paid-in capital of $134.5 million. In connection with the adoption the Company calculated an effective interest rate of 3.43%.
The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 3.00% per annum, payable semi-annually in arrears on March 1 and September 1. Upon conversion, the Convertible Notes will be convertible into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election. The Convertible Notes will be subject to redemption at the Company’s option, under certain restrictions as noted below, on or after September 1, 2021, in whole or in part, if the conditions described below are satisfied. The redemption of the Convertible Notes may also be subject to certain restrictions included in Note 7, “Term Loan and Credit Facility.” The Convertible Notes will mature on September 1, 2024, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to satisfaction of certain conditions and during the periods described below, the Convertible Notes may be converted at an initial conversion rate of 20.4891 shares of common stock per $1,000 principal amount of the Convertible Notes (equivalent to an initial conversion price of approximately $48.81 per share of common stock).
Holders of the Convertible Notes may convert all or any portion of their notes, in multiples of $1,000 principal amount, at their option at any time prior to the close of business on the business day immediately preceding June 1, 2024 only under the following circumstances:
(1)if the last reported sale price of the Company’s common stock for at least 20 trading days (whether consecutive or not) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
(2)during the five-business day period after any five-consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 principal amount of the Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;
(3)if the Company calls the Convertible Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or
(4)upon the occurrence of specified corporate events.
As of June 30, 2021, none of the above circumstances had occurred and, as such, the Convertible Notes were not convertible.
Prior to September 1, 2021, the Company may not redeem the Convertible Notes. On or after September 1, 2021, the Company may redeem for cash all or part of the Convertible Notes if the last reported sale price of the Company’s common stock equals
13

Table of Contents
or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30-consecutive trading day period ending within five trading days prior to the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. In addition, calling any Convertible Note for redemption will constitute a make-whole fundamental change with respect to that Convertible Note, in which case the conversion rate applicable to the conversion of that Convertible Note, if it is converted in connection with the redemption, will be increased in certain circumstances.
In March 2021, the Company entered into separate, privately negotiated transactions with certain holders of the Convertible Notes to repurchase $112.2 million face amount of the Convertible Notes for a cash purchase of $108.6 million. As the Company only extinguished a portion of the debt, the difference between the reacquisition price and the net carrying amount of the extinguished portion resulted in a gain on extinguishment of $2.0 million. Third party costs associated with the modification of $0.3 million were included in selling, general and administrative expense for the six months ended June 30, 2021.
The outstanding balances of the Convertible Notes as of June 30, 2021 consisted of the following (in thousands):
2024 Convertible Notes
Liability
Principal$192,753 
Less: debt discount and issuance costs, net(2,688)
Net carrying amount$190,065 
As of June 30, 2021, the debt issuance costs on the Convertible Notes will be amortized over the remaining period.
Prior to January 1, 2021, the Company separated the Convertible Notes into liability and equity components. On issuance, the carrying amount of the equity components was recorded as a debt discount and subsequently amortized into interest expense. The Company determined the expected life of the Convertible Notes was equal to their seven-year term. Effective January 1, 2021 the effective interest rate on the Convertible Notes for the period from the date of issuance through June 30, 2021 was 3.43%.
As of June 30, 2021, the “if-converted value” did not exceed the remaining principal amount of the Convertible Notes. The fair value of the Convertible Notes are based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, the Convertible Notes are classified within Level 2 in the fair value hierarchy. The fair value of the Convertible Notes, which differs from their carrying value, is influenced by interest rates, the Company’s stock price and stock price volatility. The estimated fair value of the Convertible Notes as of June 30, 2021 was approximately $178.4 million.
The following table sets forth total interest expense recognized related to the Convertible Notes during the three and six months ended June 30, 2021 and 2020 (in thousands):
Three Months Ended
June 30,
Six Months Ended June 30,
2021202020212020
Contractual interest expense$1,446 $2,288 $3,602 $4,575 
Amortization of debt discount196 4,275 489 8,409 
Amortization of debt issuance costs11 160 26 315 
Total interest expense$1,653 $6,723 $4,117 $13,299 
Future minimum payments on the Company’s Convertible Notes as of June 30, 2021 are as follows (in thousands):
14

Table of Contents
Years ended December 31,
Future Minimum Payments
2021$3,041 
20225,783 
20235,783 
2024198,535 
Total minimum payments
$213,142 
Less: interest
(20,389)
Less: unamortized discount
(2,688)
Less: current portion
 
Convertible notes payable
$190,065 
7. Term Loan and Credit Facility
On March 3, 2021, the Company and two of its wholly-owned subsidiaries, Radius Pharmaceuticals, Inc. and Radius Health Ventures, Inc. (collectively with the Company, the “Borrowers”), entered into an (i) Amended and Restated Credit and Security Agreement (Term Loan) (the “Term Credit Agreement”), with MidCap Financial Trust, in its capacity as administrative agent, and the financial institutions or other entities from time to time parties thereto as lenders (the “Term Lenders”) and (ii) Amended and Restated Credit and Security Agreement (Revolving Loan) (the “Revolving Credit Agreement,” together with the Term Credit Agreement, the “Credit Agreements”), with MidCap Funding IV Trust, in its capacity as administrative agent, and the financial institutions or other entities from time to time parties thereto as lenders.
The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $150.0 million (the “Initial Term Loan”), an increase of $125.0 million from the arrangement entered into in January 2020. In addition, the Borrowers have the right under the Term Credit Agreement to request that the Term Lenders make an additional term loan in an aggregate principal amount of $25.0 million available to the Borrowers within one year of the closing date of the Initial Term Loan (the “Initial Closing Date”). The Term Lenders are not under any obligation to provide any such additional term loan.
The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility”, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $25.0 million, the availability of which is determined based on a borrowing base as follows: (i) up to 85% of the net collectable value of the Borrowers’ domestic accounts receivable due from eligible direct and third-party payors, plus (ii) up to 40% of the Borrowers’ domestic eligible inventory, minus certain reserves; provided that the availability from eligible inventory may not exceed 20% of the borrowing base at any time.
The Facilities have a maturity date of June 1, 2024. The obligations under the Credit Agreements are guaranteed by the Borrowers and are guaranteed by certain future subsidiaries of the Borrowers, subject to certain exceptions. The obligations under the Facilities are secured by substantially all of the assets of the Borrowers, and are secured by substantially all assets of the future subsidiaries of the Borrowers that become borrowers or guarantors under the Facilities, subject to certain exceptions.
Borrowings under the Term Facility bear interest through maturity at a variable rate based upon the LIBOR rate plus 5.75%, subject to a LIBOR floor of 2.00%. Borrowings under the Revolving Facility bear interest through maturity at a variable rate based upon the LIBOR rate plus 3.50%, subject to a LIBOR floor of 2.00%. The Borrowers are required to pay a monthly commitment fee on the unused commitments under the Revolving Facility of 0.50% per annum.
On March 11, 2021, the Company received proceeds of $122.6 million under the Term Facility, net of fees and expenses of $2.4 million. With the issuance of a new term loan, the Company performed an assessment comparing the discounted cash flows of the original debt and the new debt as of the modification date, and concluded that the change is considered a modification. As of the modification date, the Company established a new effective interest rate based on the carrying value of the debt and the revised cash flows. Fees paid to the lender of $2.4 million were capitalized and will be amortized to interest expense using the effective interest method over the term of the loan. Third party costs associated with the modification of $2.8 million were included in selling, general and administrative expense for the six months ended June 30, 2021. The estimated fair value of the Term Facility as of June 30, 2021 was approximately $138.8 million. The outstanding balance of the Term Loan as of June 30, 2021 was (in thousands):
15

Table of Contents
Term loan
Principal$150,000 
Less: debt issuance costs, net(2,152)
Net carrying amount$147,848 
The following table sets forth total interest expense recognized related to the Term Facility during the three and six months ended June 30, 2021 and 2020 (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2021202020212020
Contractual interest expense$2,939 $196 $3,976 $375 
Amortization of debt discount208 1 256 2 
Total interest expense$3,147 $197 $4,232 $377 
Future minimum payments on the Term Facility as of June 30, 2021 are as follows (in thousands):
Years ended December 31,
Future Minimum Payments
2021$5,813 
202211,625 
202361,302 
2024102,260 
Total minimum payments
$181,000 
Less: interest
(31,000)
Less: unamortized issuance costs
(2,152)
Less: current portion
 
Term loan
$147,848 
16

Table of Contents
8. Net Loss Per Share
Basic and diluted net loss per share for the periods set forth below is calculated as follows (in thousands, except share and per share amounts):

Three Months Ended
June 30,
Six Months Ended
June 30,
 2021202020212020
Numerator:    
Net loss$(16,810)$(43,880)$(32,559)$(81,534)
Denominator:    
Weighted-average number of common shares used in loss per share - basic and diluted47,391,530 46,420,046 47,114,947 46,345,585 
Loss per share - basic and diluted$(0.35)$(0.95)$(0.69)$(1.76)
The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the three and six months ended June 30, 2021 and 2020, respectively, all of the Company’s options to purchase common stock and restricted stock units outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position.
Three and Six Months Ended June 30,
 20212020
Options to purchase common stock6,287,436 6,194,931 
Restricted stock units438,134 835,972 
Performance units 70,000 
Performance options1,035,000  
The Company has the option to settle the conversion obligation for the Convertible Notes in cash, shares or any combination of the two. As the Convertible Notes are not convertible as of June 30, 2021, they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on the Company’s net loss position, there is no impact on the calculation of dilutive loss per share during the three and six-month periods ended June 30, 2021 and 2020, respectively. Effective for the three months ended March 31, 2021, the Company uses the if-converted method for the Convertible Notes as a result of the adoption of ASU 2020-06, as described in Recent Adopted Accounting Pronouncements above.
17

Table of Contents
9. Product Revenue Reserves and Allowances
To date, the Company’s only source of product revenue has been from the U.S. sales of TYMLOS, which it began shipping to customers in May 2017. The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2021 and 2020 (in thousands):
Chargebacks, Discounts, and FeesGovernment and other rebatesReturnsTotal
Ending balance at December 31, 2019$5,739 $17,280 $1,583 $24,602 
Provision related to sales in the current year12,129 34,448 3,888 50,465 
Adjustments related to prior period sales(294)(826)(1,449)(2,569)
Credits and payments made(15,390)(36,805)(679)(52,874)
Ending balance at June 30, 20202,184 14,097 3,343 19,624 
Ending balance at December 31, 2020$1,891 $14,644 $2,572 $19,107 
Provision related to sales in the current year9,313 52,886 187 62,386 
Adjustments related to prior period sales(54)(989)(2,249)(3,292)
Credits and payments made(9,677)(42,859)(189)(52,725)
Ending balance at June 30, 2021$1,473 $23,682 $321 $25,476 
Chargebacks, discounts, fees, and returns are recorded as reductions of accounts receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
10. License Revenue and Reimbursable Expenses
General
The Company has generated revenue from contracts with customers, which include upfront payments for licenses.
Teijin
In July 2017, the Company entered into a License and Development Agreement (the “Teijin Agreement”) with Teijin Limited (“Teijin”) for abaloparatide-SC in Japan.
Pursuant to the Teijin Agreement, the Company granted Teijin: (i) an exclusive payment-bearing license under certain of the Company’s intellectual property to develop and commercialize abaloparatide-SC in Japan, (ii) a non-exclusive payment-bearing license under certain of the Company’s intellectual property to manufacture abaloparatide-SC for commercial supply in Japan, (iii) a right of reference to certain of the Company’s regulatory data related to abaloparatide-SC for purposes of developing, manufacturing and commercializing abaloparatide-SC in Japan, (iv) a manufacture transfer package, upon Teijin’s request, consisting of information and the Company’s know-how that is necessary for the manufacture of active pharmaceutical ingredient and abaloparatide-SC, and (v) right, at Teijin’s request, to have the Company manufacture (or arrange for a third party to manufacture) and supply (or arrange for a third party to supply) the active pharmaceutical ingredient for the clinical supply of abaloparatide-SC in sufficient quantities to enable Teijin to conduct its clinical trials in Japan. In consideration for these rights, the Company received an upfront payment of $10.0 million, and has received and may receive further payments upon the achievement of certain regulatory and sales milestones, as well as a fixed low double-digit royalty based on net sales of abaloparatide-SC in Japan during the royalty term, as defined below. In addition, the Company has an option to negotiate a co-promotion agreement with Teijin for abaloparatide-SC in Japan upon commercialization.
Pursuant to the Teijin Agreement, the parties may further collaborate on new indications for abaloparatide-SC. Abaloparatide-TD is not currently part of the Teijin Agreement.
Unless earlier terminated, the Teijin Agreement expires on the later of the (i) date on which the use, sale or importation of abaloparatide-SC is no longer covered by a valid claim under the Company’s patent rights licensed to Teijin in Japan, (ii) expiration of marketing or data exclusivity for abaloparatide-SC in Japan, or (iii) 10th anniversary of the first commercial sale of abaloparatide-SC in Japan.
The Company assessed this arrangement in accordance with Topic 606 and concluded that the contract counterparty, Teijin, is a customer. The Company identified the following material promises under the contract: the commercialization and
18

Table of Contents
manufacturing licenses under certain intellectual property rights relating to abaloparatide-SC in Japan, as well as the right of reference to certain regulatory information. In addition, the Company identified the following customer option that would create an obligation for the Company if exercised by Teijin - the transfer of manufacturing know-how. The customer option for the transfer of manufacturing know-how represents a material right. Finally, the Company also identified the following customer option that would create a manufacturing obligation for the Company if exercised by Teijin - the supply of abaloparatide-SC for Teijin’s clinical trial needs. The customer option for clinical supply of abaloparatide-SC does not represent a material right. Based on these assessments, the Company identified the (i) commercialization and manufacturing licenses, as well as the right of reference to certain regulatory information, and (ii) transfer of manufacturing know-how as the only performance obligations at the inception of the arrangement, which were both deemed to be distinct.
The Company further determined that the up-front payment of $10.0 million constituted the entirety of the consideration to be included in the transaction price, which was allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. For the commercialization and manufacturing licenses, including the right of reference to certain regulatory information, the stand-alone selling price was calculated using the expected cost approach by leveraging the direct costs incurred by the Company in its ACTIVExtend Phase 3 clinical trial for abaloparatide-SC, plus an estimated inflation rate. The stand-alone selling price of the transfer of manufacturing know-how was computed using a cost plus margin approach reflecting the level of effort required, which can be reasonably estimated to be incurred over the performance period, multiplied by a fully-burdened internal labor rate plus an expected margin. Based on the estimates of the stand-alone selling prices for each of the performance obligations, as referenced above, the Company determined that substantially all of the $10.0 million transaction price should be allocated to the performance obligation for the commercialization and manufacturing licenses, including the right of reference to certain regulatory information. The consideration allocated to the performance obligation for the transfer of manufacturing know-how was immaterial. The Company believes that a change in the assumptions used to determine its best estimate of the selling price for the commercialization and manufacturing licenses, including the right of reference to certain regulatory information, would not have a significant effect on the allocation of the underlying consideration to the performance obligations.
Upon execution of the Teijin Agreement, the transaction price included only the $10.0 million up-front payment owed to the Company. As referenced above, the Company has received and may receive further payments upon the achievement of certain regulatory and sales milestones, totaling up to $40.0 million, as well as a fixed low double-digit royalty based on net sales of abaloparatide-SC in Japan during the royalty term. The regulatory milestone, which represents variable consideration that was evaluated under the most likely amount method, was not included in the transaction price, because the amount was fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone was outside the control of the Company. Any consideration related to sales-based milestones as well as royalties on net sales upon commercialization by Teijin, will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Teijin and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.
In March 2021, Teijin received approval for Ostabaro® abaloparatide acetate for the treatment of osteoporosis and for promotion of bone formation in both female and male patients with high risk of fracture, achieving the regulatory milestone that provides for a payment of $10.0 million to the Company.
During the six months ended June 30, 2021, the Company recognized $10.0 million of license revenue upon the achievement of the regulatory milestone.
Berlin-Chemie
The Company is a party to a license agreement (“License Agreement”) with Berlin-Chemie under which the Company granted Berlin-Chemie an exclusive license to develop and commercialize products containing elacestrant (RAD1901) worldwide.
The Company and Berlin-Chemie are also parties to a Transition Services Agreement (the “TSA”), pursuant to which the Company has agreed to perform certain services for Berlin-Chemie related to the EMERALD Phase 3 monotherapy study Pursuant to the TSA, Berlin-Chemie agreed to reimburse the Company for all out-of-pocket and full-time employee costs in performing the services, for total estimated reimbursements of $114.6 million. The Company will continue to incur research and development expenses in support of scale up costs under the TSA. The agreements were entered into in July 2020.
Pursuant to the terms of the License Agreement, the Company is eligible to receive up to $20.0 million in development and regulatory milestone payments and up to $300.0 million in sales milestone payments. The Company is also eligible to receive tiered royalties on sales of licensed products at percentages ranging from low to mid-teens, subject to certain reductions.
The License Agreement will continue on a licensed product-by-licensed product and country-by-country basis until the last to expire royalty term. Either party may terminate the License Agreement for an uncured material breach by the other party or
19

Table of Contents
upon the bankruptcy or insolvency of the other party. The Company may terminate the License Agreement for certain patent challenges or if no development, manufacture or commercialization activity occurs in any given 24-month period. Berlin-Chemie may terminate the License Agreement at its discretion for any reason by delivering 180 days’ prior written notice to the Company; provided that such termination will not be effective prior to the third anniversary of the effective date.
The Company determined that the License Agreement and TSA should be combined and evaluated as a single arrangement as they were executed on the same date and negotiated as a package. The arrangement with Berlin-Chemie provides for the transfer of the following goods or services: (i) license, (ii) know-how, (iii) regulatory filings, (iv) inventory, (v) transition services, including certain clinical, manufacturing, regulatory and other services associated with the Phase 3 EMERALD monotherapy study, and (vi) participation in various joint committees.
Management applied the guidance in ASC 606 to identify all distinct goods and services within the arrangement to assess whether there is a unit of account that should be accounted for under ASC 606. Management evaluated all of the promised goods or services within the contract and determined which of those were separate performance obligations. The Company determined that the license granted, at arrangement inception, should be combined with the know-how and regulatory filings as they are not capable of being distinct (the “License”). The Company also concluded that the license rights, know-how, and regulatory filings are capable of being distinct from the supply of inventory, as Berlin-Chemie would be able to benefit from the inventory on its own or with other resources that are readily available, and capable of being distinct from the transition services and participation in joint committees as these are research and development services that can typically be performed by other third parties.
The License and the initial transfer of inventory are elements of the arrangement that are subject to the revenue recognition accounting guidance, as the performance obligations are an output of the Company’s ordinary activities in exchange for consideration. Conversely, the transition services, and the participation on joint committees are elements of the arrangements that are outside the scope of the revenue recognition guidance, as the Company is providing goods and services that are not an output of the Company’s ordinary activities.
The transaction price at inception was comprised of fixed consideration of $30.0 million. The $30.0 million upfront fee, which represents the fixed consideration in the transaction price, was allocated to the License and the supply of inventory, on a relative standalone selling price basis. The Company estimated the standalone selling price for the license by applying a risk adjusted, net present value, estimate of future potential cash flows approach and determined the standalone selling price for the inventory using a cost approach. Accordingly, the Company has allocated $27.4 million to the license and $2.6 million to the inventory. The Company concluded that the reimbursements for the research and development transition services and participation in the joint steering committees was commensurate with the standalone selling prices of the services, and as such, will be attributed to those services. The reimbursements for these services are recorded as a reduction of the related research and development expenses as the expenses are incurred.
Under the Berlin-Chemie agreements, the Company is eligible to receive various development and regulatory, and sales milestones. There is uncertainty that the events to obtain the development and regulatory milestones will be achieved. The Company has thus determined that all such milestones will be constrained until it is deemed probable that a significant revenue reversal will not occur. Additional transaction price recognized in future periods related to milestone payments and royalties will be allocated solely to the License.
Sales milestones and sales-based royalties were also excluded from the transaction price as the license is deemed to be the predominant item to which the sales milestones and sales-based royalties relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
During the six months ended June 30, 2021, the Company recorded $32.8 million as a reduction of research and development expenses for reimbursement of transition services performed under the TSA. As of June 30, 2021, we had a receivable of $37.5 million related to reimbursable research and development expenses under this agreement, which is presented in other current assets on the condensed consolidated balance sheet.
11. Commitments and Contingencies
Litigation
From time to time, the Company may become subject to legal proceedings and claims which arise in the ordinary course of its business. The Company records a liability in its condensed consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the
20

Table of Contents
possible loss or range of loss to the extent necessary to make the condensed consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.
As of June 30, 2021, the Company was not party to any significant litigation.
Kindeva
The Company is a party to a Scale-Up and Commercial Supply Agreement (the “Supply Agreement”) with Kindeva Drug Delivery (“Kindeva”), as successor to 3M Company and 3M Innovative Properties Company (collectively with 3M Company, “3M”), pursuant to which Kindeva has agreed to exclusively manufacture Phase 3 and global commercial supplies of abaloparatide-coated transdermal system product (“Product”) and associated applicator devices (“Applicator”). Under the Supply Agreement, Kindeva manufactures Product and Applicator for the Company according to agreed-upon specifications in sufficient quantities to meet the Company’s projected supply requirements. Kindeva manufactures commercial supplies of Product at unit prices that decrease with an increase in the quantity the Company orders. The Company will pay Kindeva a mid-to-low single-digit royalty on worldwide net sales of Product and reimburse Kindeva for certain capital expenditures incurred to establish commercial supply of Product. The Company is responsible for providing, at its expense, supplies of abaloparatide drug substance to be used in manufacturing Product. During the term of the Supply Agreement, Kindeva and the Company have agreed to work exclusively with each other with respect to the delivery of abaloparatide, parathyroid hormone (“PTH”), and/or PTH related proteins via active transdermal, intradermal, or microneedle technology.
The initial term of the Supply Agreement began on its effective date, February 27, 2018, and will continue for five years after the first commercial sale of Product. The Supply Agreement then automatically renews for successive three-year terms, unless earlier terminated pursuant to its terms or upon either party’s notice of termination to the other 24 months prior to the end of the then-current term. The Supply Agreement may be terminated by either party upon an uncured material breach of its terms by the other party, or due to the other party’s bankruptcy, insolvency, or dissolution. The Company may terminate the Supply Agreement upon the occurrence of certain events, including for certain clinical, technical, or commercial reasons impacting Product, if it is unable to obtain U.S. regulatory approval for Product within a certain time period, or if it ceases development or commercialization of Product. Kindeva may terminate the Supply Agreement upon the occurrence of certain events, including if there are certain safety issues related to Product, if the Company is unable to obtain U.S. regulatory approval for Product within a certain time period, or if the Company fails to order Product for a certain period of time after commercial launch of the Product in the U.S. Upon certain events of termination, Kindeva is required to transfer the manufacturing processes for Product and Applicator to the Company or a mutually agreeable third party and continue supplying Product and Applicator for a period of time pursuant to the Company’s projected supply requirements. Prior to 3M’s sale of its drug delivery business to Kindeva and 3M, the Company selected Thermo Fisher to conduct the abaloparatide-TD coating process and packaging operations. The Company has paid 3M and Kindeva approximately $40.5 million, in the aggregate, through June 30, 2021 with respect to performance under the Supply Agreement. In addition, there are cancelable purchase commitments in place to fund the facility build out and future purchases of capital equipment.
The Company is a party to a Development and Clinical Supplies Agreement with 3M, as amended (the “Development Agreement”), under which Product and Applicator development activities occurred and 3M manufactured phase 1 and 2 clinical trial supplies on an exclusive basis. The initial term of the Development Agreement remained in effect until June 2019, after which it has automatically renewed and will continue to renew for successive one-year terms, unless earlier terminated, until the earliest of (i) the expiration or termination of the Supply Agreement, (ii) the mutual written agreement of the parties, or (iii) prior written notice by either party to the other party at least ninety days prior to the end of the then-current term of the Development Agreement that such party declines to extend the term. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company pays 3M for services delivered pursuant to the agreement on a fee-for-service or a fee-for-deliverable basis as specified in the agreement. The Company has paid 3M approximately $30.2 million, in the aggregate, through June 30, 2021 with respect to services and deliverables delivered pursuant to the Development Agreement.
Manufacturing Agreements
The Company is a party to a Supply Agreement with Ypsomed AG (“Ypsomed”), as amended, pursuant to which Ypsomed agreed to supply commercial and clinical supplies of a disposable pen injection device customized for subcutaneous injection of abaloparatide. The Company has agreed to purchase a minimum number of devices at prices per device that decrease with an increase in quantity supplied. In addition, the Company agreed to make milestone payments for Ypsomed’s capital developments in connection with the initiation of the commercial supply of the device and to pay a one-time capacity fee. All costs and payments under the agreement are delineated in Swiss Francs. The agreement had an initial term of three years, which began on June 1, 2017, after which it automatically renewed for a two-year term. Following its current term, the agreement automatically renews for additional two-year terms unless either party terminates the agreement upon 18 months’ notice prior to
21

Table of Contents
the end of the then-current term. For the two-year term beginning May 2020, the Company is required to purchase a minimum number of batches for CHF 1.9 million (approximately $2.1 million).
The Company is also a party to a Commercial Supply Agreement with Vetter Pharma International GmbH (“Vetter”), as amended, pursuant to which Vetter has agreed to formulate the finished abaloparatide-SC drug product containing abaloparatide active pharmaceutical ingredient (“API”), fill cartridges with the drug product, assemble the pen delivery device, and package the pen for commercial distribution. The Company agreed to purchase the cartridges and pens in specified batch sizes at a price per unit. For labeling and packaging services, the Company agreed to pay a per unit price dependent upon the number of pens loaded with cartridges that are labeled and packaged. These prices are subject to an annual price adjustment. The agreement had an initial term of five years, which ended on January 1, 2021, and after which it renewed for an additional two-year term. It will automatically renew for additional two-year terms following the current term unless either party notifies the other party two years before the end of the then-current term that it does not intend to renew.
The Company is also a party to a Manufacturing Services Agreement with Polypeptide Laboratories Holding AB (“PPL”), as amended, as successor-in-interest to Lonza Group Ltd., pursuant to which PPL has agreed to manufacture the commercial and clinical supplies of abaloparatide API. The Company agreed to purchase the API in batches at a price per gram in euros, subject to an annual increase by PPL. The agreement has an initial term of six years, which began on June 28, 2016, after which it automatically renews for three-year terms unless either party provides notice of non-renewal 24 months before the end of the then-current term. The Company was required to purchase a minimum number of batches annually, equal to approximately €2.9 million (approximately $3.4 million) per year, subject to any annual price adjustments, during the initial term, except in calendar years 2019 and 2020.
Asset Purchase Agreement
In December 2020, the Company entered into an Asset Purchase Agreement with Fresh Cut Development, LLC and Benuvia Therapeutics Inc. for the acquisition of certain assets related to formulations of CBD related to the oral administration of a solution of CBD for therapeutic use in humans or animals. Under the terms of the agreement, the Company may be
obligated to make additional payments of up to $60.0 million in future periods, which would become due and payable only upon the achievement of certain development milestones. In addition, the Company may be obligated to pay up to $30.0 million in sales milestones contingent upon the realization of sales revenues and sublicense revenue. As of June 30, 2021, the Company recognized a liability of $2.5